Xeloda (Capecitabine) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Xeloda

Breast Cancer »

Breast cancer facts

Breast cancer is the most common cancer among American women.
One in every eight women in the United States develops breast cancer.
There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues.
The causes of breast cancer are not yet fully known although a number of risk factors have been identified.
There are many different types of breast cancer.
Breast cancer is diagnosed with physician and self-examination of the breasts, mammography, ultrasound testing, and biopsy.
Treatment of breast cancer depends on the type of cancer and its stage (the extent of spread in the body).

According to the American Cancer society:

Over 200,000 new cases of invasive breast cancer are diagnosed each year.
Nearly 40,000 women will die of breast cancer in 2011.
There are over 2...

Read the Breast Cancer article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Xeloda User Reviews >>

Xeloda

Colorectal (Colon) Cancer Slideshow Pictures

Digestive Disease Myths Slideshow Pictures

font size

OVERDOSE

The manifestations of acute overdose would include nausea, vomiting, diarrhea, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for XELODA (capecitabine) overdose has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low–molecular-weight metabolite of the parent compound.

Single doses of XELODA (capecitabine) were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m² basis).

CONTRAINDICATIONS

Dihydropyrimidine Dehydrogenase (DPD) Deficiency

XELODA (capecitabine) is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.

Severe Renal Impairment

XELODA (capecitabine) is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]) [see Use In Specific Populations and CLINICAL PHARMACOLOGY].

Hypersensitivity

XELODA (capecitabine) is contraindicated in patients with known hypersensitivity to capecitabine or to any of its components. XELODA (capecitabine) is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil.

Last reviewed on RxList: 4/6/2011
This monograph has been modified to include the generic and brand name in many instances.